Spark Therapeutics Inc Revenue Growth Rates (ONCE), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Spark Therapeutics Inc   (NASDAQ: ONCE)
 

ONCE's Revenue Growth by Quarter and Year

Spark Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ONCE Revenue (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
4th Quarter December -
3rd Quarter September 22.45
2nd Quarter June 13.50
1st Quarter March 20.77
FY 56.72





ONCE Revenue third quarter 2019 Y/Y Growth Comment
Spark Therapeutics Inc reported Revenue surge of 109.59% year on year in the third quarter 2019, to $ 22.45 millions, this is lower than Spark Therapeutics Inc 's recent average Revenue surge of 349.09%.

Looking into third quarter 2019 results within Biotechnology & Pharmaceuticals industry 12 other companies have achieved higher Revenue growth. While Spark Therapeutics Inc ' s Revenue doubling of 109.59% ranks overall at the positon no. 272 in the third quarter 2019.


ONCE Revenue ( Y/Y Growth %) 2019
 2018 2017 2016
4th Quarter December - 77.6 % -54.54 % -5.23 %
3rd Quarter September 109.59 % 463.68 % 46.15 % 0 %
2nd Quarter June -46.41 % 1602.03 % 14.73 % 0 %
1st Quarter March 32.46 % 1134.65 % -1.55 % -43.17 %
FY   - 436.82 % -40.24 % -

Financial Statements
Spark Therapeutics Inc 's third quarter 2019 Revenue $ 22.45 millions ONCE's Income Statement
Spark Therapeutics Inc 's third quarter 2018 Revenue $ 10.71 millions Quarterly ONCE's Income Statement


ONCE Revenue (Quarter on Quarter Growth %)

 2019
 2018 2017 2016
4th Quarter December - 22.88 % 290 % 1153.85 %
3rd Quarter September 66.27 % -57.48 % 28.38 % 0.78 %
2nd Quarter June -35 % 60.65 % 16.54 % 0 %
1st Quarter March 57.83 % 111.61 % -92.21 % -92.5 %
FY (Year on Year)   - 436.82 % -40.24 % -


Back to ONCE Growth rate Comparisons >> Back to ONCE Growth rate Comparisons >>


Revenue third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #87
Overall #272

Revenue Y/Y Growth Statistics
High Average Low
2701.4 % 349.09 % -88.63 %
(Jun 30 2018)   (Dec 31 2017)
Revenue third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #87
Overall #272
Revenue Y/Y Growth Statistics
High Average Low
2701.4 % 349.09 % -88.63 %
(Jun 30 2018)   (Dec 31 2017)

Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Spark Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1220.07 % 150.38 % -92.51 %
(Dec 31 2015)  


ONCE's III. Quarter Q/Q Revenue Comment
Spark Therapeutics Inc achieved in the III. Quarter 2019 below company average Revenue jump of 66.27% quarter on quarter, to $ 22.45 millions.

Although the III. Quarter 2019 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -57.48% growth in the III. Quarter a year ago

Within Biotechnology & Pharmaceuticals industry 10 other companies have achieved higher Revenue quarter on quarter growth. While Spark Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 267.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #11
Healthcare Sector #67
Overall #267
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #11
Healthcare Sector #67
Overall #267
Revenue Q/Q Growth Statistics
High Average Low
1220.07 % 150.38 % -92.51 %
(Dec 31 2015)  


ONCE's III. Quarter Q/Q Revenue Comment
Spark Therapeutics Inc achieved in the III. Quarter 2019 below company average Revenue jump of 66.27% quarter on quarter, to $ 22.45 millions.

III. Quarter 2019 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -57.48% in the III. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 10 other companies have achieved higher Revenue quarter on quarter growth. While Spark Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 267.


Spark Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)		 12 Months Ending
(Mar 31 2019)		 12 Months Ending
(Dec 31 2018)		 12 Months Ending
(Sep 30 2018)
Cumulative Revenue 12 Months Ending $ 69.88 $ 58.14 $ 69.82 $ 64.73 $ 58.98
Y / Y Revenue Growth (TTM) 18.48 % 15.88 % 163.8 % 436.44 % 181.37 %
Year on Year Revenue Growth Overall Ranking # 147 # 967 # 124 # 19 # 1067
Seqeuential Revenue Change (TTM) 20.19 % -16.73 % 7.87 % 9.75 % 17.56 %
Seq. Revenue Growth (TTM) Overall Ranking # 1001 # 2651 # 422 # 64 # 3792


Cumulative Revenue growth Comment
Although Spark Therapeutics Inc 's Annual Revenue growth year on year were below company's average 78.05% , Revenue announced in the Sep 30 2019 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 18.48% year on year, from 15.88% in Jun 30 2019.

In the Healthcare sector 40 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 147, from total ranking in previous quarter at 967.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 20
Healthcare Sector # 41
Overall # 147

Revenue TTM Y/Y Growth Statistics
High Average Low
436.44 %
 78.05 %
-40.22 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 20
Sector # 201
S&P 500 # 1001
Cumulative Revenue growth Comment
Although Spark Therapeutics Inc 's Annual Revenue growth year on year were below company's average 78.05% , Revenue announced in the Sep 30 2019 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 18.48% year on year, from 15.88% in Jun 30 2019.

In the Healthcare sector 40 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 147, from total ranking in previous quarter at 967.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 20
Healthcare Sector # 41
Overall # 147

Revenue TTM Y/Y Growth Statistics
High Average Low
436.44 %
78.05 %
-40.22 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 20
Sector # 201
S&P 500 # 1001




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ONCE's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2019 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2019
Tetraphase Pharmaceuticals Inc190.18%$ 190.182 millions
Palatin Technologies Inc 182.22%$ 182.217 millions
Guardant Health Inc 180.51%$ 180.509 millions
Regenxbio Inc 177.04%$ 177.045 millions
Zyla Life Sciences174.57%$ 174.574 millions
Scienture Holdings Inc 172.74%$ 172.744 millions
Portola Pharmaceuticals inc 159.57%$ 159.568 millions
Aerie Pharmaceuticals Inc 153.96%$ 153.958 millions
Endonovo Therapeutics Inc 153.63%$ 153.633 millions
Vbi Vaccines Inc149.81%$ 149.807 millions
Invo Fertility Inc 142.88%$ 142.880 millions
Ibio inc 140.00%$ 140.000 millions
Corbus Pharmaceuticals Holdings Inc 137.40%$ 137.404 millions
Titan Medical Inc137.13%$ 137.127 millions
Lite Strategy Inc 137.09%$ 137.090 millions
Amicus Therapeutics inc 136.78%$ 136.784 millions
Fate Therapeutics Inc 136.74%$ 136.745 millions
Chemocentryx Inc.135.79%$ 135.788 millions
Biocardia Inc 130.95%$ 130.952 millions
Igc Pharma Inc 124.54%$ 124.538 millions
United Cannabis Corp121.55%$ 121.551 millions
Cardiff Lexington Corporation120.75%$ 120.754 millions
Progyny Inc 120.15%$ 120.145 millions
Ultragenyx Pharmaceutical Inc 119.33%$ 119.332 millions
Cue Biopharma Inc 119.15%$ 119.154 millions
Healthlynked Corp117.29%$ 117.292 millions
Heron Therapeutics Inc 115.43%$ 115.425 millions
Biodelivery Sciences International Inc 114.09%$ 114.086 millions
Spark Therapeutics Inc 109.65%$ 109.648 millions
Apyx Medical Corp106.29%$ 106.291 millions


About Spark Therapeutics Inc Revenue Growth Rates (ONCE), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.